FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine
The FDA managed to process Pfizer’s Covid-19 jab in less than a third of usual time, but recently uncovered e-mails reveal that not all officials were on board with the accelerated review.
by christian bundgaard, translated by daniel pedersen
Had the decision been left to the US Food and Drug Administration’s former director of vaccine research and review, Marion Gruber, Pfizer’s Covid-19 jab would never have received accelerated review at all, reports media Endpoints News. Before it happened, she said in a hitherto unpublicized email sent to other FDA officials that fast-tracking the approval process would undermine public trust in the Covid-19 vaccine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
